Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.9%

4 terminated/withdrawn out of 31 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

138%

11 of 8 completed trials have results

Key Signals

8 recruiting11 with results

Enrollment Performance

Analytics

Phase 2
22(88.0%)
Phase 1
3(12.0%)
25Total
Phase 2(22)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials
NCT07069595Phase 2Recruiting

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

Role: collaborator

NCT03971409Phase 2Active Not Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Role: collaborator

NCT02928978Phase 2Completed

Ruxolitinib for Premalignant Breast Disease

Role: collaborator

NCT07340541Phase 2Recruiting

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Role: collaborator

NCT04841148Phase 2Recruiting

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Role: collaborator

NCT07458113Phase 2Not Yet Recruiting

Sac-TMT for Active TNBC Brain Metastases

Role: collaborator

NCT05721248Phase 2Active Not Recruiting

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Role: collaborator

NCT03368729Phase 1Active Not Recruiting

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Role: collaborator

NCT01494662Phase 2Completed

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Role: collaborator

NCT07222215Phase 2Recruiting

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Role: collaborator

NCT03095352Phase 2Completed

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Role: collaborator

NCT06774027Recruiting

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Role: collaborator

NCT04425018Phase 2Active Not Recruiting

MARGetuximab Or Trastuzumab (MARGOT)

Role: collaborator

NCT06533826Phase 2Recruiting

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Role: collaborator

NCT04443348Phase 2Active Not Recruiting

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Role: collaborator

NCT01982448Phase 2Completed

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Role: collaborator

NCT06551116Recruiting

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Role: collaborator

NCT03501979Phase 2Terminated

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Role: collaborator

NCT04584255Phase 2Active Not Recruiting

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Role: collaborator

NCT02743910Active Not Recruiting

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

Role: collaborator